Loading
FORT MYERS — NeoGenomics has created tests to identify 22 categories of cancerous tumors that will help doctors treat their patients more effectively, the company announced.
The tests will help doctors identify the most effective therapy for that particular kind of tumor based on its genetic profile. The tumors range from those in the brain, lung, breast, esophagus and other kinds of cancers.
“Precision medicine requires precision testing,” says Doug VanOort, the NeoGenomics' chairman and CEO, in a statement. “Our targeted tests are responsive to the need for both comprehensive testing in complex cases and the need to be cost-sensitive for patients and insurance companies.”
“Our molecular profiling testing is a reliable and concise approach to sub-classifying these tumors based on their underlying driving biology,” says Maher Albitar, NeoGenomics' chief medical officer and director of research and development, in the statement. “This enables clinicians to better manage and treat their patients. Our testing is designed to find actionable molecular abnormalities without testing hundreds of genes.”
In addition to its headquarters in Fort Myers, NeoGenomics has labs in Nashville, Tenn., Irvine, Cal., and Tampa. The company's shares are publicly traded (symbol: NEO; recent price: $4).
You can read a recent story about NeoGenomics in the Business Observer here.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
